Rami Levin, CEO of Saniona, a pharmaceutical company focused on rare neurological diseases describes Prader-Willi syndrome (PWS) and the latest clinical data involving PWS patients given Tesomet (tesofensine + metoprolol).

PWS is a genetic condition that leads to excessive hyperphagia that is difficult to control and can lead to  life-threatening obesity. Persons with PWS are also likely to have small stature and intellectual disabilities.

The company recently completed an exploratory randomized, double-blind, placebo-controlled Phase 2a study in patients with PWS that showed the drug to be well tolerated and effective at higher doses. A Phase 3 clinical trial is currently in development.

Tesomet consists of tesofensine, a serotonin-noradrenaline-dopamine reuptake inhibitor and metoprolol, a selective beta blocker.



To stay informed about this and other clinical trials, be sure to sign up to receive our weekly newsletter.


  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.